The Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday (9 January) announced that the novel type 2 oral polio vaccine (nOPV2) has been
quality-assured (prequalified) by the World Health Organization (WHO).
Developed by a team including scientists from the MHRA, nOPV2 is considered a safer polio vaccine that helps to protect children from the disabling and
life-threatening disease and lower the risk of vaccine-derived outbreaks.
The vaccine received WHO Emergency Use Listing three years ago, and since then 950 million doses have been delivered worldwide.
The UN health agency's decision to add it to the list of prequalified vaccines is based on the analysis of outcomes in vaccinated populations that has confirmed
strong safety profile and effectiveness.